Drug Profile


Alternative Names: INCAGN 01949; INCAGN1949

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Agenus; Ludwig Institute for Cancer Research
  • Developer Agenus; Incyte Corporation
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 14 Feb 2017 Incyte and Agenus amend licensing agreement from profit-sharing agreement to royalty bearing agreement
  • 01 Oct 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (Parenteral) (NCT02923349)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top